BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34121659)

  • 1. Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.
    Inoue Y; Nikolic A; Farnsworth D; Shi R; Johnson FD; Liu A; Ladanyi M; Somwar R; Gallo M; Lockwood WW
    Elife; 2021 Jun; 10():. PubMed ID: 34121659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
    Xie Y; Cao Z; Wong EW; Guan Y; Ma W; Zhang JQ; Walczak EG; Murphy D; Ran L; Sirota I; Wang S; Shukla S; Gao D; Knott SR; Chang K; Leu J; Wongvipat J; Antonescu CR; Hannon G; Chi P; Chen Y
    J Clin Invest; 2018 Apr; 128(4):1442-1457. PubMed ID: 29360641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer.
    Chen Y; Nowak I; Huang J; Keng PC; Sun H; Xu H; Wei G; Lee SO
    J Thorac Oncol; 2014 Jan; 9(1):50-8. PubMed ID: 24346093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.
    Wan J; Wu W
    J Exp Clin Cancer Res; 2016 Jul; 35(1):119. PubMed ID: 27456341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARHGEF19 regulates MAPK/ERK signaling and promotes the progression of small cell lung cancer.
    Wang Z; Kan G; Sheng C; Yao C; Mao Y; Chen S
    Biochem Biophys Res Commun; 2020 Dec; 533(4):792-799. PubMed ID: 32993957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
    Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
    Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
    Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
    Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells.
    Plotnik JP; Budka JA; Ferris MW; Hollenhorst PC
    Nucleic Acids Res; 2014 Oct; 42(19):11928-40. PubMed ID: 25294825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras/MAPK signaling modulates VEGFR-3 expression through Ets-mediated p300 recruitment and histone acetylation on the Vegfr3 gene in lymphatic endothelial cells.
    Ichise T; Yoshida N; Ichise H
    PLoS One; 2012; 7(12):e51639. PubMed ID: 23284731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
    Cheung HW; Du J; Boehm JS; He F; Weir BA; Wang X; Butaney M; Sequist LV; Luo B; Engelman JA; Root DE; Meyerson M; Golub TR; Jänne PA; Hahn WC
    Cancer Discov; 2011 Dec; 1(7):608-25. PubMed ID: 22586683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.
    Dong QZ; Wang Y; Tang ZP; Fu L; Li QC; Wang ED; Wang EH
    Am J Pathol; 2013 Mar; 182(3):954-64. PubMed ID: 23306155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
    Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
    Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
    Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
    J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.
    Zhang J; Sun B; Ruan X; Hou X; Zhi J; Meng X; Zheng X; Gao M
    Cancer Biol Med; 2021 Feb; 18(1):105-119. PubMed ID: 33628588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.